QMRT for Neoplastic Disorder

Technical Specification of CYTOTRON

Classification: Class II a Medical Device

Indication of use: The Device is intended to be used for Regenerative and Degenerative Tissue Engineering i.e. it can be used for regenerating tissues in-situ and to cause degeneration of uncontrolled growth of tissues

Degeneration of tissues: The current indication is for use in protein linked abnormally regenerating disorders like neoplastic disease enabling tissue apoptosis and preventing metastasis.

Contraindications: Critically patients on life support system, pregnancy patients unable to lie down for the duration of therapy, Patients with electrically, Magnetically or mechanically activated implants .(eg cardiac pacemakers,Bio stimulators, Neuro stimulators, cochlear implants, hearing aids)

MRI Incompatible implants near the target region. E.g intra medullary nail, intracranial aneurysm clips, stents, intra orbital metal fragments etc

Patients with concomitant neoplastic disease especially chondrosarcoma

Drug Interactions: The following group of drugs that use the same or similar cellular pathways as QMRT may interact with the CYTOTRON exposure like Calcium Channel Blockers and Proton Pump inhibitors in cases of malignant neoplastic disorder. Patients should be advised to take medication with different mode of actions.

Product Specifications:

The power supply Cytotron must meet these specifications

a .Voltage fluctuation +/- 10% or less

b. Voltage imbalance +/- 3% or less

c .Frequency variation+/- 4% or less

d .Voltage distortion THD =10% or less

Recommended environmental specifications

Operating Temperature range 18°C to 30°C ,Humidity range 10% to 75% RH, Atmospheric pressure 700 to 1060 hPa

Mode of usage: Continuous

Life of the equipment :Typically assessed at about ten years.

Typical operating voltage: 230 V, 50 Hz. single phase

Maximum Operating current: 12 Amps

Typical operating current: 6A

IEC classification: Type B, Class 1, IPXO

MDD classification: Class II a

Target resolution: 11.25 degrees

Power supply type: Medical grade switch mode power supply complying with EN 60001-1, EN 60001 -1-2

Frequency band: VLF ,LF,HF and VHF radio bands

Instantaneous magnetic field strength: 1mT to 6T for the time duration 2.μsec to 10msec depends on the treatment and Dosimetry value.

E-Field: Broadband; average 100 dB VinM
H-Field: Broadband ;20d (below 1 kHz)
Broadband common mods current in control cables: 100mAM 150Hz
Fuses: Mains Fuse-12A, Isolation Transformer Fuse-25A

Laser Guiding System

Output: 625 to 580 nanometer wave length less than 5 m watt Complies with CFR Part 1040 10 and 1040 11 Class A LASER application

QMRT Guns

Cell Signalling

Transmembrane Potential (TMP) is a well known cellular signaling pathway that regulates the synthesis of various proteins at the appropriate time in living cells. Many non-communicable illnesses like cancer, heart diseases and degenerative disorders like cartilage loss and different kinds of inflammation are also linked to disturbances in the protein transcription process (Cone CD. Variation of Transmembrane Potential as a basic mechanism of mitosis control: Oncology, 24: 438-470, 1970) It was thought during the last few decades that if an appropriate method could be developed to alter TMP in a controlled manner, most of these disorders that are protein linked could be corrected. The ion pump in the membrane,activates the normal cellular channels for active synthesis and gene expression of appropriate proteins in different groups for a specific function. For instance the HSP group predominantly encourages tissue regeneration and can be useful in many chronic degenerative disorders, whereas the p53 group controls cell growth, thus playing an important role in arresting mitosis, thereby finding application in treating malignant neoplastic disorders. The p53 tumour suppressor gene stops the formation of tumours by its activities. If a person inherits only a copy of p53 gene from their parents, they are predisposed to cancer and usually develop several independent tumours in a variety of tissues in early adulthood (rare condition known as Li-Fraumeni Syndrome). Mutation in p53 is found in most tumour types and contributes to the complex network of molecular events leading to tumour formation. The p53 gene has been mapped to Chromosome 17. In the cell, the p53 with a cell-division-stimulating protein (CDK2).

When p21 complexes with CDK2 the cell can not pass through to the next stage of cell division. When the p53 is mutated or fails to express, it can no longer bind to the DNA and as a consequence the p21 protein is not made available to act as the stop signal for cell division, thus the cell divides uncontrollably and forms tumours. Tissue engineering is a field of science which involves altering, modifying and inducing controlled regeneration and degeneration in biological tissues. One of the methods of engineering the tissues is by altering the signaling pathways. These pathways can be altered by various intercellular parameters such as TMP signal transduction  (ligand, receptors, and signal propagation), cell cycle check points, telomere metabolism, RNA interference, etc.

Rotational Field Quantum Magnetic Resonance therapy or QMRT is a functional method of altering one of the most prominent intercellular pathways ie. the TMP pathways. It is hypothesized over the last 24 years of research that controlled altering of the TMP by application of specifically modulated radio frequency signals in the presence of a high instantaneous magnetic field can bring about changes relating to pro-apoptotic protein groups in the tumour cells. It is known that chromosomes, following the cell signaling received as a result of variation of potential (-70 to -90 mV in healthy cells, -40 to -60 mV when infected, -20 to -30 mV in neoplastic cells, 0 mV when the cell dies) in the cytoplasmic membrane, activate the emission of messages by the genes that regulate cell dynamics for normal cell function or for mitochondrial activities for ATP production, through electromechanical resonance (also called stress responsive)

The delivered instantaneous mode, wide spectrum magnetic and RF modulations are highly cell and site specific. This is based on the proton density of the tumour tissue, the permitivity of the tumour site, and depth of penetration from skin to target tissue.

Malignant Neoplastic Disorders

Malignant neoplastic disorder commonly known as cancer, is a chronic debilitating disease with genetic and environmental aetiology. It is predicted that there will be an increase in cancer incidence worldwide, with about 15 million new cases diagnosed annually. Currently available treatment modalities for cancer (surgery, chemotherapy. radiation therapy or hormonal therapy) are known for their side effects and invasive nature, despite their benefits Thus the need for new treatments and palliative care modalities that can not only arrest tumour progression without the commonly experienced adverse effects, but can also help improve quality of life.

Tissue Engineering in Malignant Neoplastic Disorders

• QMRT beams when appropriately controlled and modulated can alter the TMP to stimulate specific groups of proteins, thus initiating one or more signaling processes.
• Studies have shown that Nuclear Magnetic Resonance (NMR) exposure sensitizes tumour cells to apoptosis (Ghibelli L. Cerella C, Cordisco S, et al. NMR exposure sensitizes tumour Cells to Apoptosis. Apoptosis 11:359- 365, 2006).
• It is hypothesized that expression of p53 group of proteins is achieved by precisely altering the TMP pathway.
• The cells continue to live in a quiescent state (vegetative form of life) until it finally attains apoptosis and are recycled by  the body.

Results and Outcome

Patient Cohort: A total of 98 patients were assigned to the study after screening .There were 55 (56.1%) female and 43 (43.9%) male patients. The mean age was 54.5 ± 13.7 years, with ages ranging from 15 to 84 years. Out of the recruited patients, 86 (male 44%, female 56 %) completed the twenty-eight days exposure as per protocol. Primary Outcome: Thirty-one patients were still alive at the end of the study period of 4 years. Comparing predicted survival intervals with actual life expectancy during the follow up, there was a significant increase in life expectancy from the predicted mean of 117 ± 46 days to the actual mean of 377 ± 307 days. (t=-8.21, p =2.13 E-12).